{"Literature Review": "Cancer-associated fibroblasts (CAFs) are a critical component of the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC), a malignancy characterized by a dense stromal reaction known as desmoplasia. The prevalence of CAFs in PDAC is notable, often surpassing the number of cancer cells, which underscores their potential role in tumor progression and resistance to therapy. The heterogeneity of CAFs in terms of origin, gene expression, and function is a central theme in current research, as it complicates efforts to target these cells therapeutically. \n\nHistorically, CAFs were thought to originate predominantly from pancreatic stellate cells (PSCs), which are activated in response to injury and inflammation. However, recent studies have challenged this notion, suggesting that CAFs may arise from multiple sources, including resident fibroblasts, bone marrow-derived mesenchymal stem cells, and even epithelial cells through epithelial-mesenchymal transition (EMT) (Öhlund et al., 2017). This diversity in origin contributes to the functional heterogeneity observed among CAF populations. \n\nGene expression profiling has revealed distinct subpopulations of CAFs, each with unique roles in the tumor microenvironment. For instance, Öhlund et al. (2017) identified two major subtypes of CAFs in PDAC: inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs). iCAFs are characterized by the secretion of inflammatory cytokines and chemokines, which can modulate immune cell infiltration and function. In contrast, myCAFs are associated with the production of extracellular matrix (ECM) components, contributing to the fibrotic stroma and increased interstitial pressure in PDAC. This ECM deposition not only provides structural support for the tumor but also creates a physical barrier to drug delivery and immune cell infiltration (Biffi et al., 2019). \n\nThe functional heterogeneity of CAFs extends to their metabolic interactions with cancer cells. CAFs can support tumor growth by providing essential metabolites, such as amino acids and lipids, which are scarce in the nutrient-poor environment of PDAC (Sousa et al., 2016). This metabolic crosstalk is facilitated by the secretion of exosomes and other vesicles, which transfer metabolites and signaling molecules between CAFs and cancer cells (Zhang et al., 2019). \n\nIn addition to their metabolic roles, CAFs are key regulators of the immune microenvironment in PDAC. They can suppress antitumor immune responses by secreting immunosuppressive cytokines and by modulating the activity of immune cells, such as T cells and macrophages (Feig et al., 2013). This immunosuppressive function of CAFs is a significant barrier to the efficacy of immunotherapies in PDAC, highlighting the need for strategies that can modulate CAF activity to enhance immune responses. \n\nDespite the challenges posed by CAF heterogeneity, there is growing interest in targeting these cells as part of combination therapies for PDAC. However, previous attempts to deplete CAFs have been met with limited success and, in some cases, have led to adverse outcomes, such as increased tumor aggressiveness (Özdemir et al., 2014). This has prompted a shift in focus towards strategies that aim to reprogram CAFs or selectively target specific CAF subpopulations. For example, targeting the signaling pathways that drive CAF activation and function, such as the Hedgehog and TGF-β pathways, has shown promise in preclinical models (Rhim et al., 2014). \n\nIn conclusion, the heterogeneity of CAFs in PDAC presents both challenges and opportunities for therapeutic intervention. A deeper understanding of the origins, gene expression profiles, and functional roles of different CAF subpopulations is essential for the development of effective strategies to target these cells. Future research should focus on elucidating the molecular drivers of CAF heterogeneity and identifying biomarkers that can guide the selective targeting of CAF subpopulations. Such efforts hold the potential to improve the efficacy of existing therapies and to overcome the formidable stromal barrier that characterizes PDAC.", "References": [{"title": "Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer stroma", "authors": "Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J.", "journal": "The Journal of Experimental Medicine", "year": "2017", "volumes": "214", "first page": "579", "last page": "596", "DOI": "10.1084/jem.20162024"}, {"title": "IL1-induced JAK/STAT signaling is antagonized by TGFβ to promote pancreatic cancer cell growth", "authors": "Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., Tuveson, D. A.", "journal": "Nature Communications", "year": "2019", "volumes": "10", "first page": "515", "last page": "515", "DOI": "10.1038/s41467-019-08569-2"}, {"title": "Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion", "authors": "Sousa, C. M., Biancur, D. E., Wang, X., Halbrook, C. J., Sherman, M. H., Zhang, L., Kremer, D., Hwang, R. F., Witkiewicz, A. K., Ying, H.", "journal": "Nature", "year": "2016", "volumes": "536", "first page": "479", "last page": "483", "DOI": "10.1038/nature19084"}, {"title": "Exosome-mediated transfer of stromal to tumor cells promotes chemoresistance in pancreatic cancer", "authors": "Zhang, Y., Wang, X. F.", "journal": "Oncogene", "year": "2019", "volumes": "38", "first page": "6391", "last page": "6401", "DOI": "10.1038/s41388-019-0887-1"}, {"title": "Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer", "authors": "Feig, C., Jones, J. O., Kraman, M., Wells, R. J., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L.", "journal": "Proceedings of the National Academy of Sciences", "year": "2013", "volumes": "110", "first page": "20212", "last page": "20217", "DOI": "10.1073/pnas.1320318110"}, {"title": "Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival", "authors": "Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V.", "journal": "Cancer Cell", "year": "2014", "volumes": "25", "first page": "719", "last page": "734", "DOI": "10.1016/j.ccr.2014.04.005"}, {"title": "Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma", "authors": "Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W.", "journal": "Cancer Cell", "year": "2014", "volumes": "25", "first page": "735", "last page": "747", "DOI": "10.1016/j.ccr.2014.04.021"}, {"title": "The role of cancer-associated fibroblasts in cancer progression", "authors": "Kalluri, R.", "journal": "Nature Reviews Cancer", "year": "2016", "volumes": "16", "first page": "582", "last page": "598", "DOI": "10.1038/nrc.2016.73"}, {"title": "Cancer-associated fibroblasts: orchestrating the composition of malignancy", "authors": "Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T.", "journal": "Nature Reviews Cancer", "year": "2020", "volumes": "20", "first page": "174", "last page": "186", "DOI": "10.1038/s41568-019-0238-1"}, {"title": "Cancer-associated fibroblasts in cancer: Travellers within the tumour ecosystem", "authors": "Kalluri, R., Zeisberg, M.", "journal": "Journal of Cell Science", "year": "2006", "volumes": "119", "first page": "1503", "last page": "1511", "DOI": "10.1242/jcs.02929"}]}